Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 1 · 25%High 0 · 0%

Botulinum toxin vs placebo

Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Botulinum toxin injection showed no clear difference in participant‐reported improvement in sialorrhea in the short term… compared with placebo (low certainty).

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
RR 3 [0.81, 11.08]
1 study · 18 participants
Low

Botulinum toxin vs placebo

Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Moderate

Botulinum toxin vs placebo

Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Low

Botulinum toxin vs placebo

Adverse effects · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Botulinum toxin injection may leads to lower adverse effects compared with placebo (low certainty).

1 finding from 1 review

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low